2020-06-24T12:00:39-05:00 2019-06-30 990 2018-07-01 730580274 Oklahoma Medical Research Foundation OKLA 4052717421 825 NE 13th Street Oklahoma City OK 73104 Tim Hassen VP and Chief Financial Officer 2020-06-24 2018 2021-01-29 14:40:06Z Tim Hassen VP and CFO 825 NE 13th Street Oklahoma City OK 73104 207118901 false X www.omrf.org X 1946 OK Oklahoma Medical Research Foundation (OMRF) is dedicated to developing a better understanding of and more effective treatments for human disease. 71 71 560 71 82071 72373 58406493 60132921 23054835 24773802 4679205 5386846 5642641 6231501 91783174 96525070 0 0 37608837 38524021 0 2024579 51600819 51008364 89209656 89532385 2573518 6992685 404739259 415080137 55574718 55619740 349164541 359460397 X OMRF is dedicated to developing a better understanding of more effective treatments for human disease. false false 35297853 0 24773802 Arthritis and Clinical Immunology/Clinical Operations - The National Institutes of Health once again named OMRF an Autoimmunity Center of Excellence, one of only 10 in the U.S. With this designation comes funding to design and launch new clinical trials for patients with diseases like lupus, rheumatoid arthritis and multiple sclerosis. Those trials include: * Testing medications to prevent the onset of lupus and RA * A pair of experimental therapies targeted at reversing damage caused by MS * A study designed to assess when it might be safe to stop lupus treatments that carry potentially toxic side effects in patients whose disease has waned 6482700 0 0 Cardiovascular Biology Research Program - In November, the FDA announced it had approved a new drug to treat sickle cell disease. The therapy, known as Adakveo, is based on discoveries made in OMRF's Cardiovascular Biology Research Program. Approval came following a 52-week clinical trial showing treatment with the drug led to a significant reduction in pain crises for sickle cell patients. The blood disorder, which affects more than 1 million people worldwide, causes excruciating pain and can lead to organ damage and even death. "I've treated people with sickle cell disease, and their suffering is extreme," says Dr. Rodger McEver, the OMRF researcher upon whose work the new drug is based. "It's the dream of every physician, and certainly every scientist, to do something that can make a difference with patients." 4168723 0 0 Aging and Metabolism Research Program - Scientists in this program study a host of different disease processes, but their work unites in a common theme: building knowledge to extend the healthspan of our aging population. In 2019, they progressed toward this goal in a variety of ways. One scientist received funding from the National Institutes of Health for novel experiments to investigate whether the brain chemical dopamine plays a role in Alzheimer's disease. Another initiated a pair of multi-year projects designed to understand osteoarthritis, with an emphasis on the effects of aging, diet and trauma in the knee joint. Finally, in a study highlighted by The New York Times, work in this program showed that, despite hope to the contrary, the widely-used diabetes drug metformin doesn't seem to be a magic bullet that will counter the effects of aging. 36884296 0 3996673 OTHER PROGRAM SERVICES INCLUDE DEPARTMENTS SUCH AS CELL CYCLE AND CANCER BIOLOGY, FUNCTIONAL AND CHEMICAL GENOMICS, LABORATORY OF COAGULATION BIOLOGY AND OTHER SCIENTIFIC AND RESEARCH SUPPORT SERVICES. 36884296 3996673 82833572 true true false true false false false false true true false false true true true true true false false true false false false true false false false false true true false true false false false false false false true true true false false false true false false false false true 151 0 true 560 true true true false false false true true true true true false false true true false false false X 71 71 true false false false false false false true true false false true true true true true true true true false OK X X Tim Hassen VP and Chief Financial Officer 4052717421 825 NE 13th Street Oklahoma City OK 73104 Albers Leigh Ann Board Member 1.0 X 0 0 0 Anoatubby Bill Board Member 1.0 X 0 0 0 Bell Sharon Board Member 1.0 X 0 0 0 Benbrook Bruce Board Member 1.0 X 0 0 0 Benham Lance Board Member 1.0 X 0 0 0 Boghetich JII Board Member 1.0 X 0 0 0 Braught Barbara Board Member 1.0 X 0 0 0 Brown Rand Board Member 1.0 X 0 0 0 Burgess Ellen Board Member 1.0 X 0 0 0 Carolina Mike Board Member 1.0 X 0 0 0 Carroll MichaeL Board Member 1.0 X 0 0 0 Cason Len Board Member 1.0 X 0 0 0 Cawley Michael Board Member 1.0 X 0 0 0 Champlin Hiram Board Member 1.0 X 0 0 0 Collins Mark Board Member 1.0 X 0 0 0 Drake Ramsey Board Member 1.0 X 0 0 0 Duncan Walt Board Member 1.0 X 0 0 0 Eagan Claire Board Member 1.0 X 0 0 0 Edwards Carl Board Member 1.0 X 0 0 0 Everest Christy Board Member 1.0 X 0 0 0 Everest Tricia Board Member 1.0 X 0 0 0 Felton Ann Board Member 1.0 X 0 0 0 Fergeson Ken Board Member 1.0 X 0 0 0 Fischer Malinda Board Member 1.0 X 0 0 0 Funke Mark Board Member 1.0 X 0 0 0 Gamble Gerald Board Member 1.0 X 0 0 0 Griffin John Board Member 1.0 X 0 0 0 Groendyke Viritinia Board Member 1.0 X 0 0 0 Haglund Jacqul Board Member 1.0 X 0 0 0 Hall Brooks Board Member 1.0 X 0 0 0 Hargis Burns Board Member 1.0 X 0 0 0 Hatfield Judy Board Member 1.0 X 0 0 0 Hawley Bill Board Member 1.0 X 0 0 0 Henry Kim Board Member 1.0 X 0 0 0 Hogan Randy Board Member 1.0 X 0 0 0 Holmes Jerome Board Member 1.0 X 0 0 0 Hudson Cliff Board Member 1.0 X 0 0 0 Irani Ronnie Board Member 1.0 X 0 0 0 Jameson Brett Board Member 1.0 X 0 0 0 Johnstone Bill Board Member 1.0 X 0 0 0 Kelly Michael Board Member 1.0 X 0 0 0 Kern Terence Board Member 1.0 X 0 0 0 Kerr Lou Board Member 1.0 X 0 0 0 Levx Harrison Board Member 1.0 X 0 0 0 Little Dan Board Member 1.0 X 0 0 0 Loughridge Bill Board Member 1.0 X 0 0 0 Mahaney Mindy Board Member 1.0 X 0 0 0 McCarty Jack Board Member 1.0 X 0 0 0 Morris Jim Board Member 1.0 X 0 0 0 Nichols Larry Board Member 1.0 X 0 0 0 Parry Richard Board Member 1.0 X 0 0 0 Patten Rebecca Board Member 1.0 X 0 0 0 Payne Bond Board Member 1.0 X 0 0 0 Pierson Gary Board Member 1.0 X 0 0 0 Pitman Don Board Member 1.0 X 0 0 0 Pollard Barry Board Member 1.0 X 0 0 0 Rainbolt David Board Member 1.0 X 0 0 0 Replogle Dee Board Member 1.0 X 0 0 0 Rooney Pat Board Member 1.0 X 0 0 0 Ross Bob Board Member 1.0 X 0 0 0 Samis Mike Board Member 1.0 X 0 0 0 Saxon John Board Member 1.0 X 0 0 0 Schulte Paul Board Member 1.0 X 0 0 0 Stougn Phyllis Board Member 1.0 X 0 0 0 Swimmer Ross Board Member 1.0 X 0 0 0 Switzer Becky Board Member 1.0 X 0 0 0 Taylor Steven Board Member 1.0 X 0 0 0 Thorpe Beisy Board Member 1.0 X 0 0 0 Walton Greg Board Member 1.0 X 0 0 0 Williams G Rainey Jr Board Member 1.0 X 0 0 0 Yauk Sarah Board Member 1.0 X 0 0 0 Prescott Stephen President and CEO 50.0 X 1063348 0 42060 James Judith VP of Clinical Affairs and Program Chair 50.0 X 458846 0 100061 McEver Rodger VP of Research and Member 50.0 X 328321 0 41145 Morgan Chip Executive VP & Chief Operating Officer 50.0 X 254462 0 39772 Cohen Adam Sr VP and General Counsel 50.0 X 256486 0 43153 Hassen Tim VP and CFO 50.0 X 246235 0 50562 Voss Penny VP of Development 50.0 X 222877 0 62431 Nair Manu VP of Technology Transfer 50.0 X 233856 0 44153 Courtney Greenwood VP of Human Resources 50.0 X 158483 0 33352 Day Lisa VP of Business and Government Affairs 50.0 X 136110 0 21207 Pardo Gabriel Associate Member, Arthritis and Clinical Immunoid 50.0 X 335185 0 47123 Xia Lijun Program Chair and Cardiovascular Biology 50.0 X 277637 0 67943 Jones David Program Chair, Functional and Chemical Genomics 50.0 X 306251 0 47123 Gaffney Patrick Program Chair, Arthritis and Clinical Immunology 50.0 X 301896 0 57242 Nath Swapan Member, Arthritis and Clinical Immunology 50.0 X 263452 0 48126 Rezale Alizera Member, Cardiovascular Biology 50.0 X 249527 0 39084 Lupu Florea Member, Cardiovascular Biology 50.0 X 246815 0 32863 5339787 0 817400 59 false true false Infusion Management LLC 11233 Shadow Creek Pwky Pearland TX 77584 Medical Billing Services 17973886 Aramark 24863 Network Pl Chicago IL 606731248 HouseKeeping Services 513837 Mcallister & Quinn LLC 1368 N Washington Ave Scranton PA 18509 Grant application review services 152000 Exaptive Inc 309 NW 13th St Oklahoma City OK 73103 Pilot research project assistance 125000 4 103776 540331 31452033 28036781 861639 60132921 Clinic Revenue 621990 24773802 24773802 0 0 0 0 24773802 11442564 14360 11428204 116278 116278 3330094 1684970 1645124 374255 0 0 0 374255 0 374255 374255 102746070 1544002 109913636 548432 -7167566 995570 -6171996 67711 -6239707 64604 540331 131763 -67159 -67159 Laboratory Income 621500 2311703 2311703 Cafe Income 722514 282608 282608 0 0 0 0 2594311 96525070 28770475 82071 7539603 3971844 3067985 680982 222877 25767931 23744284 1033360 990287 1670164 1505758 96276 68130 5218993 4512401 526020 180572 1895089 1708541 109242 77306 102427 72733 29694 113400 113400 64455 64455 1359542 1359542 0 0 568395 336061 77608 154726 1184544 970986 174781 38777 3780448 3012626 767744 78 770419 680356 63522 26541 133217 132451 766 886015 870766 15249 7829195 7489289 339906 301008 213744 87264 Lab supplies 6042285 6042285 Trainee costs 1183320 1183320 Inhouse 1693521 1657918 22491 13112 Subcontracts 22432503 22432503 2563670 1840023 471474 252173 89532385 82833572 4674234 2024579 4200 3640 22699110 20330349 6573788 8527729 4945865 5264915 0 0 0 102500 52500 13070 12735 288761 524743 234948705 136682537 100420755 98266168 110679441 121232724 13632479 15002777 0 0 0 145379290 145861857 404739259 415080137 10458467 13066821 0 0 1795563 1060576 37605000 34810000 0 0 0 0 0 0 0 0 5715688 6682343 55574718 55619740 X 113467709 120292368 42961441 45807340 192735391 193360689 349164541 359460397 404739259 415080137 X 6992685 2934671 0 0 0 368500 X false true X true true true X 51509291 55448766 58391949 58406493 60132921 283889420 0 0 0 0 0 0 0 0 0 0 0 0 51509291 55448766 58391949 58406493 60132921 283889420 49978828 233910592 6537705 6651582 6182195 8549189 13575846 41496517 0 0 0 5304 81073 86377 724249 287716 732460 334103 347212 2425740 327898054 87973722 0.7134 0.7317 X Schedule A, Part II, Line 10 Other Income DESCRIPTION - , COLUMN A - 724249.0, COLUMN B - 287716.0, COLUMN C - 732460.0, COLUMN D - 334103.0, COLUMN E - 347212.0, COLUMN F - 2425740.0; RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED false true false false false false true 420331 false false 420331 false Schedule C, Part II-B, Line 1 DETAILED DESCRIPTION OF THE LOBBYING ACTIVITY The Foundation's lobbying activities entail monitoring proposed legislation and educating legislators and their staffs about the Foundation, medical research and the impact of proposed legislation on medical research and the Foundation. 97512842 16719850 5906286 0 4200000 0 115938978 91545136 75342 9892364 0 4000000 0 97512842 82018035 246125 13280976 0 4000000 0 91545136 86604791 389217 -1175973 0 3800000 0 82018035 86302560 1057014 2745217 0 3500000 0 86604791 0.2232 0.4766 0.3002 true false 3944520 3944520 183335585 101311594 82023991 47049478 35370943 11678535 619122 619122 98266168 Funds held in trust by others 137793022 Wills and Bequests 3620090 Cash Surrender Value of Life Insurance 3940291 Debt Issue Costs 208013 Deposits 123847 Accrued Interest Receivable 128515 Assets Held for Sale 47970 Minerals 109 145861857 Postretirement Benefits and Deferred Comp 6560962 Split Interest Agreements 121381 6682343 X 99828241 2934671 0 0 368500 3303171 96525070 0 0 0 96525070 89532385 0 0 0 0 0 89532385 0 0 0 89532385 Schedule D, Part V, Line 4 Intended uses of endowment funds The Foundation's endowment consists of individual funds established to provide the Foundation with funding in perpetuity. Schedule D, Part X, Line 2 FIN 48 (ASC 740) footnote The Foundation is a public foundation exempt from federal income tax under section 501(c)(3) of the internal revenue code except for amounts relating to unrelated business income. There were no known material unrelated business income taxes incurred in 2019 and accordingly, no provision for income taxes has been made in these financial statements. Management has reviewed the Foundation's tax position and concluded that there are no uncertain tax positions that require accrual in the consolidated financial statements or disclosure in the footnotes to be in compliance with authoritative literature. Generally, the Foundation is no longer subject to income tax examination by federal, state or local tax authorities for years prior to 2016. The statute of limitations will remain open for both federal and state purposes for any returns not filed. Schedule D, Part XI, Line 2(d) Other revenues in audited financial statements not in form 990 Changes in fair value of Funds Held in Trust - 498639 Pension related changes other than net periodic pension costs - -130139 East Asia and the Pacific 0 6 Conference Travel 16350 Europe (Including Iceland and Greenland) 0 21 Conference Travel 81632 Europe (Including Iceland and Greenland) 0 1 Program Services Program Project Review 2770 North America (Canada & Mexico only) 0 9 Conference Travel 14107 South America 0 2 Conference Travel 3414 South Asia 0 1 Program Services Intellectual Property/Research Collaboration 2867 Europe (Including Iceland and Greenland) 0 15 ,Education 25026 North America (Canada & Mexico only) 0 1 ,Board Relations 2171 North America (Canada & Mexico only) 0 0 Investments 677147 Central America and the Caribbean 0 0 Investments 667703 0 56 0 0 0 56 1493187 0 1493187 true false false true true false Schedule F, Part I, Line 3 Program service activity in all regions includes scientists attending and/or speaking at scientific conferences and collaborations. OMRF does not maintain ongoing operations in foreign jurisdictions, however the Foundation's scientists do travel to various scientific conferences in other countries to share in scientific discoveries, as well as to learn from other scientists across the world. 241 Event 604935 540331 64604 7920 19210 17892 36130 50611 0 0 604935 540331 64604 7920 19210 17892 36130 50611 131763 -67159 X X X true true X X X X X false true false false false false false true false Prescott Stephen President and CEO 795327 0 223979 0 44042 0 30356 0 11704 0 1105408 0 0 0 James Judith VP of Clinical Affairs and Program Chair 405599 0 9375 0 43872 0 89408 0 10653 0 558907 0 0 0 McEver Rodger VP of Research and Member 277610 0 6792 0 43919 0 30041 0 11104 0 369466 0 0 0 Morgan Chip Executive VP & Chief Operating Officer 216679 0 10268 0 27515 0 26236 0 13536 0 294234 0 0 0 Cohen Adam Sr VP and General Counsel 200816 0 10510 0 45160 0 32885 0 10268 0 299639 0 0 0 Hassen Tim VP and CFO 222403 0 10360 0 13472 0 32060 0 18502 0 296797 0 0 0 Voss Penny VP of Development 193321 0 9114 0 20442 0 44704 0 17727 0 285308 0 0 0 Nair Manu VP of Technology Transfer 204601 0 9375 0 19880 0 26693 0 17460 0 278009 0 0 0 Courtney Greenwood VP of Human Resources 147661 0 6542 0 4280 0 16802 0 16550 0 191835 0 0 0 Day Lisa VP of Business and Government Affairs 123704 0 5579 0 6827 0 11214 0 9993 0 157317 0 0 0 Pardo Gabriel Associate Member, Arthritis and Clinical Immunoid 333913 0 0 0 1272 0 29671 0 17452 0 382308 0 0 0 Xia Lijun Program Chair and Cardiovascular Biology 251808 0 125 0 25704 0 50491 0 17452 0 345580 0 0 0 Jones David Program Chair, Functional and Chemical Genomics 305279 0 0 0 972 0 29671 0 17452 0 353374 0 0 0 Gaffney Patrick Program Chair, Arthritis and Clinical Immunology 287084 0 100 0 14712 0 39790 0 17452 0 359138 0 0 0 Nath Swapan Member, Arthritis and Clinical Immunology 239140 0 0 0 24312 0 30014 0 18112 0 311578 0 0 0 Rezale Alizera Member, Cardiovascular Biology 206052 0 0 0 43475 0 26913 0 12171 0 288611 0 0 0 Lupu Florea Member, Cardiovascular Biology 201940 0 0 0 44875 0 26040 0 6823 0 279678 0 0 0 Schedule J, Part I, Line 3 Compensation for the CEO is determined by leadership of the board of directors based on comparability data from widely accepted peer benchmarking surveys that are segmented by region and size of entity. Schedule J, Part I, Line 1a First-class or charter travel First class travel is allowed for the CEO to allow him to accomplish work related to tasks while traveling. Schedule J, Part I, Line 1a Travel for companions Travel for companions is allowed in certain limited circumstances where the companion's presence has a benefit to the Foundation but does not qualify as a business expense under IRS rules. In those limited cases the companion's travel expenses are treated as taxable compensation. Schedule J, Part I, Line 1a Discretionary spending account Also, the CEO can expend up to $10,000 per fiscal year in additional compensation for reimbursement of non-qualified business expenses. Schedule J, Part I, Line 4b Supplemental nonqualified retirement plan The Board of the Foundation periodically uses non-qualified retirement plans as a retention tool. The amount reported is the amount vested in the 457(f) plan. The remaining amount of the plan is not vested and is subject to substantial risk of forfeiture. Schedule J, Part I, Line 7 Non-fixed payments The CEO receives an annual bonus that is determined by leadership of the board of directors based on performance. The bonus is considered as a portion of total compensation and is subject to the review process previously described. A Oklahoma Industries Authority Revenue Bonds (OMRF Project) Series 2010 736194355 000000000 2010-05-26 12185000 Refunding of Prior year 2001 bond false false false B Oklahoma Industries Authority Revenue Bonds (OMRF Project) Series 2016 736194355 000000000 2016-07-13 29535000 Refunding of prior year 2008 bond false false false A 0 0 12185000 96500 0 11946495 142005 0 0 0 0 0 2010 true true true true B 6910000 0 29535000 2953564 0 26315325 266175 0 0 0 0 0 2016 false true true true A false false false true true 0.0 0.0 0.0 false false true B false false false true true 0.0 0.0 0.0 false false true A true false false false false true B false true false false false false false false true A true B true Schedule K, Part I 05/26/2010 12185000 Oklahoma Industries Authority In May 2010, the Foundation issued 12,185,000 of Oklahoma Industrial Authorities ("OIA") Series 2010 Revenue Bonds (the "Series 2010 Bonds") dated May 1, 2010. The proceeds from the Series 2010 Bonds were used to retire the OIA 2001 Series Bonds on February 1, 2011. The Series 2010 Bonds mature February 1, 2021 and bear interest at the stated rate of 4.375% per annum. Interest payments began July 1, 2010 and are due on August 1st and February 1st of each year through 2021, at which time the principal will be due in its entirety. The Series 2010 bonds were issued with no premium or discount. The Series 2010 Bond agreements also require maintenance of a reserve fund which is included in investments in the accompanying statement of financial position. This amount was approximately $1,218,400 as of June 30, 2019. Schedule K, Part I 07/13/2016 29535000 Oklahoma Industries Authority In July 2016, the Foundation entered into advanced refinancing of the Series 2008 bonds. The Foundation issued $43,955,000 of OIA Series 2008 Revenue Bonds (the "Series 2008 Bonds") dated July 1, 2008; the proceeds from this bond were used to construct and equip a new research facility. The Series 2008 Bonds were defeased when the Foundation issued $29,535,000 of OIA Series 2016 Revenue Bonds (the "Series 2016 Bonds") dated July 13, 2016. The Series 2016 bonds mature on July 1, 2026 and bear interest at the stated rate of 1.81% per annum. Payments of principal and interest began January 1, 2017 and are due January 1st and July 1st of each year. The Series 2016 Bond agreements also require maintenance of a reserve fund which is included in investments in the accompanying statement of financial position. This amount was $2,953,500 as of June 30, 2019. Michelle Morgan Related to Officer 14238 Employment false X 19 861639 Market value 0 false true false Form 990, Part III, Line 4d Description of other program services (Expenses $ 36,884,296 including grants of $ 0)(Revenue $ 3,996,673) OTHER PROGRAM SERVICES INCLUDE DEPARTMENTS SUCH AS CELL CYCLE AND CANCER BIOLOGY, FUNCTIONAL AND CHEMICAL GENOMICS, LABORATORY OF COAGULATION BIOLOGY AND OTHER SCIENTIFIC AND RESEARCH SUPPORT SERVICES. Form 990, Part VI, Line 1a Delegate broad authority to a committee The Foundation's Board of Directors has delegated all of its powers to the Foundation's Executive Committee, except as follows: establish the overall policies and direction of the Foundation, appoint members of the Executive Committee, elect and remove the Chair of the Board of Directors, amend the Bylaws and the Certificate of Incorporation of the Foundation, and appoint special committees to the Board of Directors. The Board of Directors may at any time amend or revoke this delegation of powers. Form 990, Part VI, Line 11b Review of form 990 by governing body The Form 990 is prepared by the Foundation, internally reviewed by the CFO. The Form 990-T is externally reviewed by the tax department of a public accounting firm. A summary of Form 990 is presented for review to the Executive Committee. Subsequent to that review, the form 990 with all supplemental schedules is made available to all members of the board of directors for review and comment prior to filing. Form 990, Part VI, Line 12c Conflict of interest policy Each director, officer and key employee is annually provided with a copy of the Foundation's conflict of interest policy. Each of these individuals is annually provided with a questionnaire regarding potential conflicts and required to disclose any potential conflict that he or she might have. In addition, each of these individuals must annually sign a statement affirming that he or she has; received a copy of the conflicts of interest policy, read and understood the policy and agrees to comply with the policy. Once the Foundation has collected annual disclosure statements from all directors, officer and key employees, the Foundation's Governance Committee reviews such information to identify situations in which a potential conflict exists and is material. If a potential material conflict is identified, the committee analyzes whether the contemplated transaction may be authorized as just, fair, and reasonable to the Foundation. The Governance Committee then makes a recommendation to the Foundations' Executive Committee regarding the management of all potential conflicts it has identified. The final decision as to the approval and, where applicable, management of all such potential conflict rests in the sole discretion of the Executive Committee, which makes such decisions based upon the welfare of the Foundation and the advancement of its purpose. The recommendations of the Governance Committee and decisions of the Executive Committee are documented in the respective minutes of these Committees' regular meetings. Form 990, Part VI, Line 15a Process to establish compensation of top management official Compensation for officers and key employees is determined and evaluated in May of each year by the executive committee of the board of directors based on comparability data from widely accepted peer benchmarking salary surveys that are segmented by region and size of entity. Form 990, Part VI, Line 15b Process to establish compensation of other employees Compensation for officers and key employees is determined and evaluated in May of each year by the executive committee of the board of directors based on comparability data from widely accepted peer benchmarking salary surveys that are segmented by region and size of entity. Form 990, Part VI, Line 18 How forms are made available to the public The Foundation's Form 990 for the last three years are publicly available on the Foundation's website, as well as on Guidestar and other nonprofit databases. Form 1023, 990, and 990-T are provided upon request. Form 990, Part VI, Line 19 Required documents available to the public The Foundation's governing documents, conflict of interest policy, and financial statements are provided upon request and are publicly available on the foundation's website. Form 990, Part XI, Line 9 Other changes in net assets or fund balances Other changes in net assets or fund balances - 368500; Form 990, Part VI Section A, Line 2 The Foundation currently has 71 directors, many of whom are business leaders and members of prominent families in the State of Oklahoma. The Foundation believes there are multiple business relationships between and among board members and families of Board members, but the Foundation review of signed conflict of interest disclosures from all board members and of the Foundation's ledger accounts indicated there are no such relationships that would impair the fiduciary duties of any director to the Foundation. Culbertson Plaza LLC 825 NE 13th Street Oklahoma City OK 73104 842527142 Manage real property known as the Culbertson Plaza Shopping Center OK 0 50000 Oklahoma Medical Research Foundation